New insights into myocardial glucose metabolism: Surviving under stress

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 12, Issue 4, 2009, Pages 424-430

  Patterson, Brandy ^a   Fields, Anjali V ^b   Shannon, Richard P ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AMP kinase; Glucose uptake; Glut transporters; Hypoxia induced factor 1 ; Ischemic preconditioning

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENYLATE KINASE; AMIODARONE; CALCIUM; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE TRANSPORTER 4; HYPERTENSIVE AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INCRETIN; INOTROPIC AGENT; INSULIN; METFORMIN; SULFONYLUREA;

CLINICAL TRIAL; DIABETIC PATIENT; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; MUSCLE STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

BIOLOGICAL TRANSPORT; GLUCOSE; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; HUMANS; INSULIN; MYOCARDIAL ISCHEMIA; MYOCARDIUM; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 68049093113     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e32832c4167     Document Type: Review

References (30)

1. Neubauer S. Mechanisms of disease: the failing heart - an engine out of fuel. N Engl J Med 2007; 356:1140-1151.
2. Bertrand L, Horman S, Beauloye C, Vanoverschelde JL. Insulin signaling in the heart. Cardiovasc Res 2008; 79:238-248. An excellent summary of insulin-signaling mechanisms in myocardium.
3. Watson RT, Pessin JE. GLUT4 translocation: the last 200 nanometers. Cell Signal 2007; 19:2209-2217.
4. Sano H, Eguez L, Teruel MN, et al. Rab10, a target of the AS160 Rab GAP, is required for insulin-stimulated translocation of GLUT4 to the adipocyte plasma membrane. Cell Metab 2007; 5:293-303.
5. Ishikura S, Bilan PJ, Klip A. Rabs 8A and 14 are targets of the insulin-regulated Rab-GAP AS160 regulating GLUT4 traffic in muscle cells. Biochem Biophys Res Commun 2007; 353:1074-1079.
6. Lanner JT, Bruton JD, Katz A, et al. Ca(2+) and insulin-mediated glucose uptake. Curr Opin Pharmacol 2008; 8:339-345.
7. Sharma S, Guthrie PH, Chan SS, et al. Glucose phosphorylation is required for insulin-dependent mTOR signalling in the heart. Cardiovasc Res 2007; 76:71-80.
8. Ni YG, Wang N, Cao DJ, et al. FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases. Proc Natl Acad Sci U S A 2007; 104:20517-20522.
9. Dyck JR, Lopaschuk GD. AMPK alterations in cardiac physiology and pathology: enemy or ally? J Physiol 2007; 574:95-112.
10. Omar MA, Fraser H, Clanachan AS. Ischemia-induced activation of AMPK does not increase glucose uptake in glycogen-replete isolated working rat hearts. Am J Physiol Heart Circ Physiol 2008; 294:H1266-H1273. This article describes an important observation in reconciling previously conflicting data on the role of AMPK in ischemia.
11. Miller EJ, Li J, Leng L, et al. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 2008; 451:578-582. Novel and important new insights into the relationship between myocardial substrate utilization and inflammation are described in this article.
12. Stuck BJ, Lenski M, Böhm M, et al. Metabolic switch and hypertrophy of cardiomyocytes following treatment with angiotensin II are prevented by AMPactivated protein kinase. J Biol Chem 2008; 283:32562-32569. An important demonstration of metabolic shifts that accompany cardiac hypertrophy.
13. Dawn B, Bolli R. HO-1 induction by HIF-1: a new mechanism for delayed cardioprotection? Am J Physiol Heart Circ Physiol 2005; 289:H522-H524.
14. Ytrehus K. Hypoxia-inducible factor 1 alpha: a new piece in the preconditioning puzzle. Cardiovasc Res 2008; 77:443-444. A succinct review of new information linking HIF-1α and preconditioning.
15. Taylor CT. Mitochondria and cellular oxygen sensing in the HIF pathway. Biochem J 2008; 409:19-26.
16. Kelly RF, Sluiter W, McFalls EO. Hibernating myocardium: is the program to survive a pathway to failure? Circ Res 2008; 102:3-5.
17. Halestrap AP, Clarke SJ, Khaliulin I. The role of mitochondria in protection of the heart by preconditioning. Biochim Biophys Acta 2007; 1767:1007-1031.
18. Murphy E, Steenbergen C. Preconditioning: the mitochondrial connection. Annu Rev Physiol 2007; 69:51-67.
19. Ockaili R, Natarajan R, Salloum F, et al. HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation. Am J Physiol Heart Circ Physiol 2005; 289:H542-H548.
20. Belaidi E,BeguinPC, Levy P, et al. Prevention of HIF-1 activation andiNOSgene targeting by low-dose cadmium results in loss of myocardial hypoxic preconditioning in the rat. Am J Physiol Heart Circ Physiol 2008; 294:H901-H908. The above article establishes a critical link between HIF-1α and a critical mediator of ischemic preconditioning.
21. Bartrons R, Caro J. Hypoxia, glucose metabolism and the Warburg's effect. J Bioenerg Biomembr 2007; 39:223-229.
22. Brahimi-Horn MC, Chiche J, Pouysségur J. Hypoxia signaling controls metabolic demand. Curr Opin Cell Biol 2007; 19:223-229.
23. Cai Z, Zhong H, Bosch-Marce M, et al. Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1 alpha. Cardiovasc Res 2008; 77:463-470. The above article provides conclusive evidence of the role of HIF-α in ischemic preconditioning in mice.
24. Eckle T, Kö hler D, Lehmann R, et al. Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation 2008; 118:166-175. This article shows that the inhibition of HIF-1a using siRNA prevents ischemic preconditioning.
25. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008; 117:2340-2350. An excellent mechanistic study of the effects of GLP-1 on ischemia-reperfusion injury.
26. Sokos GG, Bolukoglu H, German J, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007; 100:824-829.
27. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559. A critical randomized trial of the effects of tight glycemic control on cardiovascular outcomes.
28. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572. A critical study of the role of sulfonylureas-based intensive treatment in type 2 diabetes cardiovascular and renal outcomes in type 2 diabetes.
29. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577-1589. Anunprecedented report of extensive follow-up of theUKPDSstudy demonstrating a time-dependent effect on reducing adverse cardiovascular events in type 2 diabetes
30. Chalmers J, Cooper ME. UKPDS and the legacy effect. N Engl J Med 2008; 359:1618-1620.